HSCS

HeartSciences

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 3

consensus rating "Strong Buy"

ample liquidity

Net Income Plunges

EPS Below Expectations

Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About HSCS

Heartsciences Inc.

A medical technology company that provides solutions to understand heart disease

Industry

Healthcare Equipment and Supplies

Established Date

Invalid Date

Listing Date

06/15/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

04-30

Website

www.heartsciences.com

Security Type

Common stock

Office address

550 Reserve St, Suite 360, Southlake, Texas 76092

Business

Introduction

HeartSciences Inc., was incorporated in Texas in August 2007. They are a medical technology company focused on applying innovative artificial intelligence-based technologies to electrocardiograms to expand and improve the clinical usefulness of electrocardiograms. Their goal is to make ECG a more valuable cardiac screening tool, especially in front-line or bedside clinical settings. HeartSciences' first FDA-approved product candidate, MyoVistawavECG, is a resting 12-lead electrocardiogram that is also designed to provide diagnostic information related to cardiac dysfunction traditionally only available through the use of cardiac imaging.

Company Financials

EPS

HSCS has released its 2025 Q2 earnings. EPS was reported at -2.27, versus the expected -2.34, beating expectations. The chart below visualizes how HSCS has performed over recent quarters, highlighting trends in earnings surprises.